☆ 4.7 Article

Blood pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes

HYPERTENSION (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Cardiac & Cardiovascular Systems

Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine

Rajiv Agarwal et al.

Summary: This review covers the development of mineralocorticoid receptor antagonists (MRAs) over the last 80 years, discussing the differences in mechanisms and effects between nonsteroidal and steroidal MRAs. Nonsteroidal MRAs demonstrate important distinctions in distribution, binding mode, and gene expression compared to steroidal MRAs.

EUROPEAN HEART JOURNAL (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes

Gerasimos Filippatos et al.

Summary: The FIDELIO-DKD trial demonstrated that Finerenone reduced the incidence of cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes, with a composite outcome including cardiovascular death, myocardial infarction, stroke, and hospitalization for heart failure. There was no difference in the treatment effect based on preexisting cardiovascular disease status, with similar incidence of adverse events between treatment arms.

CIRCULATION (2021)

添加到收藏夹

Article Peripheral Vascular Disease

Effect of Mineralocorticoid Receptor Blockade on Arterial Stiffness and Endothelial Function A Meta-Analysis of Randomized Trials

Atsushi Sakima et al.

Summary: This study showed that mineralocorticoid receptor antagonists have beneficial effects on arterial stiffness, augmentation index, and flow-mediated dilation. MRA treatment reduced PWV and had comparable effects on different forms of PWV.

HYPERTENSION (2021)

添加到收藏夹

Review Urology & Nephrology

KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease Abstracts

[Anonymous]

KIDNEY INTERNATIONAL (2021)

添加到收藏夹

Article Medicine, General & Internal

Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes

Bertram Pitt et al.

Summary: Finerenone therapy improved cardiovascular outcomes in patients with type 2 diabetes and stage 2 to 4 CKD with moderately elevated albuminuria or stage 1 or 2 CKD with severely elevated albuminuria, compared to placebo. The risk of the primary outcome event was significantly lower in the finerenone group, primarily driven by a reduction in hospitalization for heart failure.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine

Rajiv Agarwal et al.

Summary: This review summarizes the development of mineralocorticoid receptor antagonists over the past 80 years, focusing on the mechanisms of action and advantages of nonsteroidal MRAs.

EUROPEAN HEART JOURNAL (2021)

添加到收藏夹

Article Medicine, General & Internal

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

George L. Bakris et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Review Urology & Nephrology

Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis

Jonatan Barrera-Chimal et al.

KIDNEY INTERNATIONAL (2019)

添加到收藏夹

Review Peripheral Vascular Disease

Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trials

Maria-Eleni Alexandrou et al.

JOURNAL OF HYPERTENSION (2019)

添加到收藏夹

Article Urology & Nephrology

Hypertension in CKD: Core Curriculum 2019

Elaine Ku et al.

AMERICAN JOURNAL OF KIDNEY DISEASES (2019)

添加到收藏夹

Article Urology & Nephrology

Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial

George L. Bakris et al.

AMERICAN JOURNAL OF NEPHROLOGY (2019)

添加到收藏夹

Article Peripheral Vascular Disease

Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone's Antifibrotic Activity

Jana Grune et al.

HYPERTENSION (2018)

添加到收藏夹

Article Urology & Nephrology

Masked Hypertension and Elevated Nighttime Blood Pressure in CKD: Prevalence and Association with Target Organ Damage

Paul E. Drawz et al.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)

添加到收藏夹

Review Pharmacology & Pharmacy

Emerging Roles of the Mineralocorticoid Receptor in Pathology: Toward New Paradigms in Clinical Pharmacology

F. Jaisser et al.

PHARMACOLOGICAL REVIEWS (2016)

添加到收藏夹

Article Medicine, General & Internal

Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial

Bryan Williams et al.

LANCET (2015)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury

Peter Kolkhof et al.

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2014)

添加到收藏夹

Review Urology & Nephrology

Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation?

Pantelis A. Sarafidis et al.

KIDNEY INTERNATIONAL (2014)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial

Bertram Pitt et al.

EUROPEAN HEART JOURNAL (2013)

添加到收藏夹

Article Peripheral Vascular Disease

2013 ESH/ESC Guidelines for themanagement of arterial hypertension The Task Force for the management ofarterial hypertension of the European Society ofHypertension (ESH) and of the European Society of Cardiology (ESC)

Giuseppe Mancia et al.

JOURNAL OF HYPERTENSION (2013)

添加到收藏夹

Article Urology & Nephrology

Hypertension in Diabetic Nephropathy: Epidemiology, Mechanisms, and Management

Peter N. Van Buren et al.

ADVANCES IN CHRONIC KIDNEY DISEASE (2011)

添加到收藏夹

Article Peripheral Vascular Disease

Nocturnal Hypertension and Chronic Kidney Disease

Michio Fukuda et al.

CURRENT HYPERTENSION REVIEWS (2011)

添加到收藏夹

Editorial Material Urology & Nephrology

Chronic kidney disease, diabetes, and hypertension: what's in a name?

Andrew S. Levey et al.

KIDNEY INTERNATIONAL (2010)

添加到收藏夹

Article Peripheral Vascular Disease

Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension

David A. Calhoun et al.

JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION (2008)

添加到收藏夹

Article Peripheral Vascular Disease

Correlates of systolic hypertension in patients with chronic kidney disease

R Agarwal et al.

HYPERTENSION (2005)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Recommendations for blood pressure measurement in humans and experimental animals - Part 1: Blood pressure measurement in humans - A statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research

TG Pickering et al.

CIRCULATION (2005)

添加到收藏夹

Article Peripheral Vascular Disease

The role of spironolactone in the treatment of patients with refractory hypertension

J Ouzan et al.

AMERICAN JOURNAL OF HYPERTENSION (2002)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.